Kiudro

Mesalazine, the active ingredient in Kiudro, is a aminosalicylate presented as a rectal formulation for rectal use. It is used to treat ulcerative colitis and other inflammatory bowel disease conditions by reducing inflammation in the colon.

GNH USA supplies Kiudro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kiudro, an aminosalicylate, is employed in the management of inflammatory bowel disease conditions.

Ulcerative colitis: reduces colonic inflammation and helps achieve remission. Inflammatory bowel disease: contributes to maintenance of disease control. Proctitis: delivers targeted anti‑inflammatory action to the rectal mucosa.

Mesalazine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rectal irritation or burning sensation - Abdominal pain or cramping - Nausea or mild vomiting - Headache - Flatulence or bloating - Diarrhea

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Blood in stool or severe gastrointestinal bleeding - Hepatotoxicity or liver enzyme elevation - Pancreatitis - Severe colitis or perforation - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When using Kiudro, certain precautions should be observed to ensure safety.

Monitor renal function: assess kidney parameters before and during therapy. Monitor hepatic function: check liver enzymes periodically. Avoid in known hypersensitivity: discontinue if allergic reactions occur. Use caution in pregnancy: discuss risks with a healthcare professional. Use caution in severe ulcerative colitis: consider alternative therapies if disease is extensive. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mesalazine can interact with several medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - NSAIDs: heightened renal toxicity. - Sulfasalazine: additive gastrointestinal toxicity. - Azathioprine: potential for enhanced myelosuppression.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in efficacy. - Diuretics: may affect renal clearance. - ACE inhibitors: monitor renal function when combined. - Live vaccines: immunogenic response may be diminished.